Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 19, Issue 12, 2000, Pages 915-925

  Maschmeyer, G ^a   Braveny, I ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZLOCILLIN; BETA LACTAM ANTIBIOTIC; CEFALEXIN; CEFOPERAZONE; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; OFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TIMENTIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTEREMIA; BACTERICIDAL ACTIVITY; CANCER PATIENT; CLINICAL FEATURE; COMORBIDITY; FEVER; GRAM NEGATIVE INFECTION; HEALTH CARE QUALITY; HEMATOPOIETIC SYSTEM TUMOR; HOSPITAL PATIENT; HUMAN; INCIDENCE; INTENSIVE CARE; MORTALITY; NEUTROPENIA; OUTPATIENT; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PSEUDOMONAS AERUGINOSA; SOLID TUMOR;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CLINICAL TRIALS; HUMANS; INCIDENCE; NEOPLASMS; PROGNOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 0034468607     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960000410     Document Type: Article

References (106)

1. Causes of death in adults with acute leukemia
2. Gram-negative bacillary pneumonia in the compromised host
3. Infections caused by Pseudomonas aeruginosa
4. Pseudomonas bacteremia. Retrospective analysis of 410 episodes
5. Polymicrobial septicemia in the cancer patient
6. Bacteremia and fungemia in patients with neoplastic disease
7. Nosocomial infection rates at an oncology center
8. Changing epidemiology of infections in patients with neutropenia and cancer: Emphasis on gram-positive and -resistant bacteria
9. Science and pragmatism in the treatment and prevention of neutropenic infection
10. The changing pattern of infection in neutropenic patients
11. The changing epidemiology of bacteremia in neutropenic children with cancer
12. Changing etiology of bacteremia in patients with hematological malignancies in Denmark
13. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution
14. Septicemia in granulocytopenic patients: A shift in bacterial etiology
15. Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones
16. From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
17. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America
18. Fever in immunocompromised patients
19. Is monotherapy for febrile neutropenia still a viable alternative?
20. Bacteremia in granulocytopenic patients in a tertiary-care general hospital
21. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes
22. Trimethoprim-sulfamethoxazole plus amikacin as first-line therapy and imipenem/cilastatin as second empirical therapy in febrile neutropenic patients with hematological disorders
23. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy
24. Ten-year survey of incidence of infection as a cause of death in hematologic malignancies: Study of 90 autopsied cases
25. Randomized trial comparing netilmicin plus imipenem-cilastatin versus netilmicin plus ceftazidime as empiric therapy for febrile neutropenic bone marrow transplant recipients
26. Risk factors and attributable mortality associated with superinfections in neutropenic patients with cancer
27. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
28. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths
29. The clinical significance of positive blood cultures in the 1990s: A prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults
30. Infections in adults with cancer in a developing country: A three year prospective study
31. The spectrum of bacterial infections in febrile neutropenic patients: Effect on empiric antibiotic therapy
32. Infection in immunocompromised patients with malignant blood disorders in a district general hospital
33. Changes in the incidence and etiological patterns of bacteremia associated with acute leukemia over a 25-year period
34. Bacterial isolates in neutropenic febrile patients
35. Bacteremia and fungemia in pediatric versus adult cancer patients after chemotherapy: Comparison of etiology, risk factors and outcome
36. Bacteremia in patients with hematological malignancies. Analysis of risk factors, etiological agents and prognostic indicators
37. Infection analysis in acute lymphoblastic leukemia: A report of 499 consecutive episodes in India
38. Fever and neutropenia in children with malignant disease
39. Outpatient antimicrobial protocol for febrile neutropenia: A nonrandomized prospective trial using ceftriaxone, amikacin, and oral adjuvant agents
40. Nosocomial infections in an oncology intensive care unit
41. Bacteremia in patients with hematologic malignancies
42. Infectious complications during remission induction therapy in 577 patients with acute myeloid leukemia in the Japan Adult Leukemia Study Group studies between 1987 and 1991
43. Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials
44. Imipenen-resistant Ps. Aeruginosa bacteraemia in cancer patients: Risk factors, clinical features and outcome
45. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis
46. Analysis of 553 episodes of monomicrobial bacteraemia in cancer patients: Any association between risk factors and outcome to particular pathogen?
47. Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies
48. Evolution of bacterial susceptibility to antibiotics during a six-year period in a haematology unit
49. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia
50. Early empiric antibiotic therapy for febrile neutropenia patients at low risk
51. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: A prospective randomized pilot study
52. Interventional antimicrobial therapy in febrile neutropenic patients
53. Prospective multicentric study of the etiology of 1051 bacteremic episodes in 782 cancer patients. CEMIC (French-Belgian Study Club of Infectious Diseases in Cancer)
54. Prospective study of bacteraemia in cancer patients. Results of a French multicentre study
55. Pseudomonas aeruginosa-still a frequent pathogen in patients with cancer, 11-year experience at a comprehensive cancer center
56. Trends in bacterial infections in febrile neutropenic patients: 1986-1992
57. Changing patterns of infections in the immunocompromised patient with cancer
58. Trends in bacteremia among cancer/marrow transplant patients during 1991-1995
59. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients
60. Outpatient therapy with oral ofloxacin for patients with low-risk neutropenia and fever: A prospective, randomized clinical trial
61. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors
62. Single-agent therapy for infections in cancer patients: A prospective randomized trial comparing three extended-spectrum cephalosporins
63. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients
64. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daffy doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia
65. Febrile neutropenia in cancer patients in Kuwait: Microbial spectrum and outcome
66. Bacteremic pneumonia in neutropenic patients with cancer: Causes, empirical antibiotic therapy, and outcome
67. Pseudomonas aeruginosa bacteremia in immunocompromised children: Analysis of factors associated with a poor outcome
68. Comparison of imipenem versus cefuroxime plus tobramycin as empirical therapy for febrile granulocytopenic patients and efficacy of vancomycin and aztreonam in case of failure
69. Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients
70. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia
71. Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients
72. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: A comparative study
73. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
74. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
75. Cefotaxime plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with hematologic malignancies
76. Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients
77. Ceftizoxime plus ticarcillin: Double beta-lactam therapy for infections in cancer patients
78. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children
79. A randomized clinical trial of ceftriaxone and teicoplanin versus ceftazidime and teicoplanin as antibiotic therapy in febrile neutropenic cancer patients and bone marrow transplant recipients
80. Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: A randomised trial
81. An open, randomized, multicentre study comparing the use of low-dose ceftazidime or cefotaxime, both in combination with netilmicin, in febrile neutropenic patients
82. Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients
83. Ceftriaxone and amikacin versus ceftazidime and amikacin in febrile granulocytopenia
84. Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia
85. Trimethoprim-sulfamethoxazole plus amikacin versus ceftazidime monotherapy as empirical treatment in patients with neutropenia and fever
86. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial
87. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes
88. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: A meta-analysis
89. Monotherapy versus betalactam-aminoglycoside combination treatment for gram-negative bacteremia: A prospective, observational study
90. Ceftriaxone monotherapy in the treatment of low-risk febrile neutropenia
91. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy
92. Self-administered antibiotic therapy for chemotherapy-induced, low-risk febrile neutropenia in patients with nonhematologic neoplasms
93. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial
94. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer
95. Risk factors for bloodstream infections at a cancer center
96. The epidemiology of Pseudomonas aeruginosa in oncology patients in a general hospital
97. Prognosis of infections in elderly patients with haematological diseases
98. Gram-negative bacteremia in non-neutropenic patients: A 3-year review
99. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia
100. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia
101. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients
102. Monotherapy for fever and neutropenia in cancer patients: A randomized comparison of ceftazidime versus imipenem
103. Septicemia in patients with hematological disorders and neutropenia. A retrospective study of causative agents and their resistance profile
104. Transplant related septicaemia in patients undergoing autologous bone marrow transplantation for lymphoma and acute leukaemia
105. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: A prospective, randomized multi-clinic study
106. Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia